158 related articles for article (PubMed ID: 15618197)
1. Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU.
Rabin SD; Hauser AR
Infect Immun; 2005 Jan; 73(1):573-82. PubMed ID: 15618197
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.
Pankhaniya RR; Tamura M; Allmond LR; Moriyama K; Ajayi T; Wiener-Kronish JP; Sawa T
Crit Care Med; 2004 Nov; 32(11):2293-9. PubMed ID: 15640644
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.
Sato H; Frank DW; Hillard CJ; Feix JB; Pankhaniya RR; Moriyama K; Finck-Barbançon V; Buchaklian A; Lei M; Long RM; Wiener-Kronish J; Sawa T
EMBO J; 2003 Jun; 22(12):2959-69. PubMed ID: 12805211
[TBL] [Abstract][Full Text] [Related]
4. A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells.
Rabin SD; Veesenmeyer JL; Bieging KT; Hauser AR
Infect Immun; 2006 May; 74(5):2552-61. PubMed ID: 16622190
[TBL] [Abstract][Full Text] [Related]
5. Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity.
Veesenmeyer JL; Howell H; Halavaty AS; Ahrens S; Anderson WF; Hauser AR
Infect Immun; 2010 Aug; 78(8):3346-57. PubMed ID: 20479080
[TBL] [Abstract][Full Text] [Related]
6. Activation of ExoU phospholipase activity requires specific C-terminal regions.
Schmalzer KM; Benson MA; Frank DW
J Bacteriol; 2010 Apr; 192(7):1801-12. PubMed ID: 20097856
[TBL] [Abstract][Full Text] [Related]
7. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors.
Phillips RM; Six DA; Dennis EA; Ghosh P
J Biol Chem; 2003 Oct; 278(42):41326-32. PubMed ID: 12915403
[TBL] [Abstract][Full Text] [Related]
8. Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity.
Tam C; Lewis SE; Li WY; Lee E; Evans DJ; Fleiszig SM
Exp Eye Res; 2007 Dec; 85(6):799-805. PubMed ID: 17905228
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU.
Zhang A; Veesenmeyer JL; Hauser AR
Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993456
[TBL] [Abstract][Full Text] [Related]
10. ExoU is a potent intracellular phospholipase.
Sato H; Frank DW
Mol Microbiol; 2004 Sep; 53(5):1279-90. PubMed ID: 15387809
[TBL] [Abstract][Full Text] [Related]
11. Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU.
Tamura M; Ajayi T; Allmond LR; Moriyama K; Wiener-Kronish JP; Sawa T
Biochem Biophys Res Commun; 2004 Apr; 316(2):323-31. PubMed ID: 15020221
[TBL] [Abstract][Full Text] [Related]
12. A novel phosphatidylinositol 4,5-bisphosphate binding domain mediates plasma membrane localization of ExoU and other patatin-like phospholipases.
Tyson GH; Halavaty AS; Kim H; Geissler B; Agard M; Satchell KJ; Cho W; Anderson WF; Hauser AR
J Biol Chem; 2015 Jan; 290(5):2919-37. PubMed ID: 25505182
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa ExoU, a toxin transported by the type III secretion system, kills Saccharomyces cerevisiae.
Rabin SD; Hauser AR
Infect Immun; 2003 Jul; 71(7):4144-50. PubMed ID: 12819106
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a phospholipase A1 activity type three secreted protein, PP_ExoU from Pseudomonas plecoglossicida NB2011, the causative agent of visceral granulomas disease in large yellow croaker (Larimichthys crocea).
Zhang J; Wang Y; Guo H; Mao Z; Ge C
J Fish Dis; 2017 Jun; 40(6):831-840. PubMed ID: 27734506
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa.
Gendrin C; Contreras-Martel C; Bouillot S; Elsen S; Lemaire D; Skoufias DA; Huber P; Attree I; Dessen A
PLoS Pathog; 2012; 8(4):e1002637. PubMed ID: 22496657
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of SpcU, a chaperone required for efficient secretion of the ExoU cytotoxin.
Finck-Barbançon V; Yahr TL; Frank DW
J Bacteriol; 1998 Dec; 180(23):6224-31. PubMed ID: 9829931
[TBL] [Abstract][Full Text] [Related]
17. Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU.
Lee VT; Pukatzki S; Sato H; Kikawada E; Kazimirova AA; Huang J; Li X; Arm JP; Frank DW; Lory S
Infect Immun; 2007 Mar; 75(3):1089-98. PubMed ID: 17178785
[TBL] [Abstract][Full Text] [Related]
18. Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU.
Finck-Barbançon V; Frank DW
J Bacteriol; 2001 Jul; 183(14):4330-44. PubMed ID: 11418575
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa Type III Secretory Toxin ExoU and Its Predicted Homologs.
Sawa T; Hamaoka S; Kinoshita M; Kainuma A; Naito Y; Akiyama K; Kato H
Toxins (Basel); 2016 Oct; 8(11):. PubMed ID: 27792159
[No Abstract] [Full Text] [Related]
20. Interactions of the effector ExoU from
Springer TI; Reid TE; Gies SL; Feix JB
J Biol Chem; 2019 Dec; 294(50):19012-19021. PubMed ID: 31662432
[No Abstract] [Full Text] [Related]
[Next] [New Search]
